Field of the Invention

This invention is in the field of genetic engi¬ neering and is directed to a method for high level polypeptide or protein production in transformed host cells.

Background of the Invention

Genetic engineering can be used to express or pro¬ duce heterologous (foreign) polypeptides or proteins in transformed host cells. By these methods, a he¬ terologous gene coding for the desired polypeptide or protein is inserted into an expression vector which is then introduced into the host cells. The replication system of the transformed host cells then reproduces the inserted gene. Under proper • conditions, the re¬ plicated gene is expressed, producing both the host cell protein and the heterologous polypeptide or pro¬ tein. The heterologous polypeptide or protein yield depends on a number of factors, including the copy number of the heterologous gene, the efficiency of the replication system of the host cell, and the type of promoters operably linked to the heterologous gene which encodes for the desired, polypeptide or protein.

Gene amplification can be used to increase the copy number of a plasmid or gene which a host cell contains. Although the use of a gene amplification system can result in high copy number of the desired heterologous gene, expression of the heterologous gene to produce the heterologous protein has not always proved successful.

In one study, Lau et al. , Molecular and Cellular Biology, 4_:1469-1475 (1984), the dihydrofolate reduc- tase gene amplification system was used to increase the copy number of a heterologous human gene in Chi¬ nese hamster ovary cells. In this study, a mammalian inducible promoter, metallothionein, was used to con¬ trol the expression of the human globin gene. After induction of the metallothionein promoter with cad¬ mium, transcription of the gene occurred, but the amount of messenger RNA produced was insufficient to support translation into the globin protein.

In another study, inducible expression occurred, but at relatively low yields. Page, M. , Gene, 37.139- 144 (1985) describes the expression of human beta- interferon genes, amplified by the dihydrofolate re- ductase system, in Chinese hamster ovary cells. The beta-interferon gene was operably linked to the induc¬ ible promoter metallothionein, which was induced by cadmium sulfate. The results showed only a 1.2 to 10.7 increase in production of the beta-interferon than that produced without induction (Table I).

Many proteins of interest are synthesized by bio¬ logical systems in minute quantities, which restricts progress toward understanding their function and medi¬ cal application. Larger quantities of the protein

would enable the purification and utilization of these proteins in therapeutic application. Genetic engi¬ neering cloning techniques are capable of isolating genes encoding these proteins. Further, genetic engi¬ neering techniques may be able to synthesize large quantities of these proteins in transformed host sys¬ tems. For a number of reasons, including the glyco- sylation patterns and secondary structures of some of these proteins, synthesis in a mammalian host cell expression system is preferable.

^• It would be desirable to have a method for high level polypeptide or protein production, including heterologous polypeptides or proteins, in a gene am¬ plification systen using an inducible promoter, such that after the gene amplification, the copy number of the heterologous gene in the host cell is significant, and upon induction, the inducible promoter retains a high level of inducibility, resulting in high level production of the desired polypeptide or protein.

Summary of the Invention

This invention provides for a method of high level polypeptide or protein production, including produc¬ tion of heterologous polypeptides and proteins, in a transformed host cell using a gene amplification sy¬ stem with an inducible heat shock promoter.

The invention was achieved in a method which com¬ prises the steps of:

(a) transforming a host cell with a heterologous gene encoding for a polypeptide or protein, under the control of a heat shock promoter;

(b) amplifying the copy number of said heterolo¬ gous gene in said transformed host cells using an am¬ plification system under the control of a promoter other than an inducible heat shock promoter?

(c) indμcing said inducible promoter by heat shocking said transformed host cells at a temperature and for a time sufficient to transcribe said heterolo¬ gous gene; and

(d) allowing said heat shocked cells to recover at a lower temperature than said heat shock tempera¬ ture and for a time sufficient to translate said tran¬ scribed heterologous gene, producing said heterologous polypeptide or protein.

This invention also provides for a method of high level production of a heterologous polypeptide or pro¬ tein under the control of an inducible heat shock pro¬ moter in a transformed mammalian host cell, using the dihydrofolate reductase gene amplification system to substantially increase the copy number of the hetero¬ logous gene.

Description of the Figures

Figure la shows schematically the genetic map of the pCVSVE 11-DHFR plasmid. Figure lb shows schema¬ tically the genetic map of the pHS-CMYC plasmid.

Figure 2 shows the copy number of c-myc constructs in recombinant cell lines.

Figures 3A and 3B show the presence, inducibility, and stability of c-myc mRNA in recombinant CHO cells. Figure 3C shows a comparison of c-myc mRNA sequences in Balb c/3T3, CHO-DUKX Bl cells and cells from recom¬ binant CHO cell lines.

Figures 4A and 4B show the time course induction of c-myc protein and analysis of protein levels in induced cells. Figure 4C shows the radiolabelling of cells after heat shock and the immunoprecipitation of the myc protein.

Definitions

In the description that follows, a number of terms used in recombinant DNA technology are extensively utilized. In order to provide a clearer and consis¬ tent understanding of the specification and claims, including the scope to be given such terms, the fol¬ lowing definitions are provided.

Promoter. A DNA sequence generally described as the 5 ¹ region of gene, located proximal to the start codon. At the promoter region, transcription or ex¬ pression of an adjacent gene(s) is initiated.

Polynucleotide molecule. A linear sequence of nucleotides linked together by a backbone consisting of an alternating series of sugar and phosphate resi¬ dues and as used herein can include DNA and RNA poly¬ mers.

Gene. A DNA sequence that contains information for construction of a polypeptide or protein, and as used herein, includes the 5' and 3* ends.

Structural gene. A DNA sequence that is trans¬ cribed into messenger RNA that is then translated into a sequence of amino acids characteristics of a speci¬ fic polypeptide. Typically the first nucleotide of the first translated codon is numbered +1, and the nucleotides are numbered consecutively with positive integers through the translated region of the struc-

tural gene and into the 3 ¹ untranslated region. The numbering of nucleotides in the promoter and regula¬ tory region 5' to the translated region proceeds con¬ secutively with negative integers with the 5 ¹ nucleo- tide next to the first translated nucleotide being numbered -1.

Heterologous gene. A structural gene that is for¬ eign, i.e. originating from a donor different from the host or chemically synthesized gene, and can include a donor of a different species from the host. The gene codes for polypeptide ordinarily not produced by the organism susceptible to transformation by the expres¬ sion vehicle.

Operably linked. As used herein means that the promoter controls the initiation of the expression of the polypeptide encoded by the structural gene.

Expression. Expression is the process by which a structural gene produces a polypeptide. It involves transcription of the gene into messenger RNA (mRNA) and the translation of such mRNA into polypeptide(s) .

Cloning vehicle. A plasmid or phage DNA or other DNA sequence which is able to replicate in a host cell, which is characterized by one or a limited num¬ ber of endonuclease recognition sites at which such DNA sequence may be cut in a determinable fashion without loss of an essential biological function of the DNA, and which contain a phenotypic selection marker suitable for use in the identification of transformed cells. Markers, for example, are tetra- cycline resistance or ampicillin resistance. The word "vector" is sometimes used for cloning vehicle.

Expression vehicle. A vehicle similar to a clon¬ ing vehicle but which is capable of expressing a given structural gene in a host, normally under control of certain regulatory sequences.

Amplification. An increase in the copy number of a gene or plasmid.

Overexpression. Production of a protein at signi¬ ficantly higher levels than is present in a normal cell.

Copy number. The number of molecules, per genome, of a plasmid or gene which a cell contains.

Constitutive. An organism is said to be consti¬ tutive for the production of an enzyme or other pro¬ tein if that protein is always produced by the cell under all physiological conditions.

Inducible. A gene or gene-product is said to be inducible if its transcription or synthesis is in¬ creased by exposure of the cells to an effector. For example, an inducible heat shock promoter is induced by the presence of high temperature.

Transformation or Transformed. A mechanism of gene transfer which involves the uptake of DNA by a host cell. Following entry into the cell, the trans¬ forming DNA may recombine with that of the host or may replicate independently as a plasmid.

Translation. The process of protein synthesis carried out by ribosomes which de-code the information contained in messenger RNA.

Transcription. The process of RNA synthesis upon a DNA template, mediated by RNA polymerase.

Detailed Description of the Invention

This invention provides for a method for high le¬ vel production of a heterologous polypeptide or pro¬ tein in a transformed host cell. The invention is based on the discovery that an inducible heat shock promoter operably linked to a heterologous gene, when amplified to a significant copy number, still retains a high level of inducibility. Using, this method, in¬ creased production of the heterologous polypeptide or protein is achieved. Further, the method of this in¬ vention is particularly useful for the expression of heterologous polypeptides or proteins whose overex- pression would impair growth of the host cell.

In the method of this invention, the heterologous gene encoding for the desired polypeptide or protein is under the control of an inducible heat shock promo¬ ter. The inducible heat shock promoter comprises one with no or low basal levels of transcription. Thus, prior to induction, this type of promoter will not express, or will express only very small quantities of, the polypeptide or protein under its control. Ex¬ amples of inducible heat shock promoters with a low basal level of transcription include the Drosophila melanogaster 70,000 dalton heat shock protein gene promoter (hsp 70) described by Holmgren et al.. Cell, 18: 1359-1370 (1979) and characterized in Amir et al. , Molecular and Cellular Biology, _5:197-203 (1985) and in Corces et al. , J. Biological Chemistry, 259:14812- 14817 (1984). Heat shock promoters from a variety of eukaryotic organisms appear to be induced by a similar mechanism; indeed the sequence element responsible for induction is conserved from the fruitfly drosophila to

humans (Pelham, Cell, 30: 517-528 (1982). Thus, any heat shock promoter isolated from a eukaryotic source, such as the drosophila hsp 22 and hsp 26 promoters (Ayme et al., J. Molecular Biology, 182: 469-475 (1985)), are examples of promoters that could be used in this system.

The inducible heat shock promoter can be obtained by isolating the heat shock gene from Drosophila, and then obtaining the promoter region enzymatically, chemically, or both. Similar promoters exist in every characterized eukaryotic species, and any of these species could be used as a source for the heat shock promoter. Further, the heat shock promoter may be synthesized de novo; for example, by manipulation in the laboratory rather than of natural origin.

In one embodiment of this invention, the heat shock promoter is operably linked to a structural gene and the resulting genetic construct is introduced in¬ to, or forms part of, an expression vehicle. The ex¬ pression vehicle is then utilized to transform an ap¬ propriate host cell.

In another embodiment of this invention, the heat shock promoter is operably linked to a genetic se¬ quence coding for a first polypeptide, and this gene¬ tic sequence is operably linked to a second genetic sequence coding for another polypeptide. The expres¬ sion yields a fusion or precursor protein comprising both the amino acid sequence of the second polypeptide and that of the desired first polypeptide, and con¬ taining a selective cleavage site between them adja¬ cent to the desired amino acid sequence.

The cleavage site is preferable methionine, al¬ though this site may be any preferred site known in the art. The desired polypeptide should preferably lack internal cleavage sites corresponding to the ac¬ tual selected cleavage site. Other known cleavage sites include asn-gly, asp-pro, lys, arg, and lys-arg. Selective cleavage of the fusion or precursor protein is typically effected outside of the replica- tive environment in the expression vehicle. In this post-translational step, the fusion or precursor pro¬ tein is clipped by selective treatment. For example, when methionine is the cleavage site, the fusion or precursor protein is treated with cyanogen bromide to clip the desired polypeptide. With other known cleav¬ age sites, the clipping treatment includes hydroxyla- mine, acid, trypsin, and lys-arg cleavage enzyme.

Methods for preparing fused, operably linked genes and expressing the same are known and are shown, for example, in U.S. patent 4,366,246.

Typically the desired structural genetic sequence is heterologous to the host cells, that is, it is not naturally produced, by that host cell. Alternatively, the desired structural genetic sequence may be pro¬ duced by the host cells, but in small quantities. Therefore, by use of the present invention, the yield of the desired protein can be increased.

After the transformation of the host cell, the copy number of the heterologous gene is increased through a gene amplification system. Gene amplifica¬ tion systems which can be used in the method of this invention are well known in the art, and may include dihydrofolate reductase (DHFR) amplification systems

- li ¬

as described in U.S. Patent No. 4,399,216 to Axel et al. (columns 26-30). Other known methods of producing high copy numbers of a gene in cells include the ade- noisine dea inase amplification system; or the use of vectors, such as SV40 or bovine papilloma virus (Mulligan, R. et al. Nature, 277: 108-114(1979); Lowy, D. P. et al, Nature, 287: 72-74 (1980), that allow autonomous replication in mammalian cells.

In the preferred method of this invention, the gene amplification system is the dihydrofolate reduc¬ tase system (DHFR). This method involves transforming a DHFR-deficient host cell with an expresion vector containing the DHFR DNA. Transformed host cells with an altered phenotype, DHFR , can then be selected, and grown in the presence of increasing concentrations of methotrexate (MTX), which is an inhibitor of DHFR. Cells grown in increasing concentrations of MTX devel¬ op resistance to the drug by overproducing the DHFR enzyme, as a result of the amplification of the DHFR genes within the host cells ¹ genome. When a cloning vehicle containing a heterologous gene of interest is cotransformed with the cloning vehicle containing the DHFR gene, it is known that both genes are amplified together under the selection pressure.

Thus, according to this invention, the gene ampli¬ fication system is used to increase significantly the copy number of the heterologous gene operably linked to a heat shock inducible promoter. As will be under¬ stood by those skilled in the art, the copy number will vary from cell to cell and will depend upon the gene amplification system used. It is contemplated by

this invention that the copy number of the heterolo¬ gous gene will be significant, that is, more than about 100 copies per cell, more preferably greater than about 1,000 copies per cell.

After gene amplification, with the increased copy number, the heat shock promoter is induced by heat shock to the transformed host cells at a temperature and for a time sufficent to transcribe the heterolo¬ gous gene. As is known in the art, the function of the promoter is totally defined by the cell type, for example, the drosophila hsp70 promoter is induced by different conditions in different cell types. There¬ fore, the heat shock temperature will depend upon the cell type used, but will typically be at 40°C to about 45°C. The period of time for the heat shock will also depend upon the host cell type used, but will typically be about 15 minutes to about 180 minutes. During the heat shock, the heterologous gene is transcribed to messenger RNA, which is the template for the desired heterologous polypeptide or protein.

The heat shocked cells are then allowed to recover from the elevated temperatures of the heat shock. Typically the cells may be cultured at a lower tem¬ perature and for a time sufficient to translate the transcribed heterologous gene. By allowing the heat shocked host cells to recover from the heat shock, the induced transcribed heterologous gene (messenger RNA) is translated into high levels of the desired hetero¬ logous polypeptide or protein. The recovery tempera¬ ture and time will depend upon the host cell used, but will typically be a recovery temperature of about 35°C to about 39°C and a recovery time of about- 60 minutes to about 600 minutes.

The methods of this invention can preferably be used to express any polypeptide or protein. Examples of such polypeptides or proteins include, but are not

limited to, enzymes, hormones, antibodies, structural proteins, interferons, interleukins, insulin, etc. The method of this invention can preferably be used to express structural gene products which impair growth of the host cells when they are overexpressed. Exam¬ ples of such polypeptides or proteins include, but are not limited to, oncogenes, such as c-myc.

In the preferred embodiment of this invention, the heterologous gene is operably linked to the Drosophila heat shock protein 70 (hsp 70) promoter. An expres¬ sion vector containing this genetic construct cotrans- for s a DHFR-deficient host cell, with an expression vector containing the DHFR gene under the control of a constitutive promoter. Constitutive promoters which may be operably linked to the DHFR gene include adeno- virus late, EII, SV40 early and the like.

The genetic construct and methods involved herein can be utilized for expression of the polypeptides or proteins in mammalian host cells. The use of mamma¬ lian host cells are preferable when the desired struc¬ tural gene to be expressed is a mammalian protein. The mammalian host cells are preferable with respect to glycosylation, phosphorylation, or other secondary modifications involved in mammalian protein systhesis. Examples of mammalian host cells include but are not limited to, Chinese hamster ovary cells (CHO), Namalva cells (Wurm et al. , Devel. Biol Standard, 60: 393-404 (1985); BHK 21 cells (Radlett et al.. Applied Mikro- biol., 2 -. 534-537 (19871); Mouse L cells (Hauser et_ al.. Nature, 297: 650-654 (1982); and Vero Cells (Whittaker and Hayward, Develop. Biol. Standard, 60: 125-131 (1985).

In general, plasmid or viral (bacteriophage) vec¬ tors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. These vec¬ tors ordinarily carry a replication site, and one or more unique restriction sites.

The cotransformed host can be fermented and cul¬ tured according to means known in the art to achieve optimal cell growth. Using the DHFR system, the host cells are grown in the presence of methotrexate. The concentrations of methotrexate are increased in a step-wise fashion, increasing the resistance of the host cells to methotrexate and providing for increased amplification of the gene. For example, initial cul¬ tures are carried in .005 uM methotrexate. Concentra¬ tions are increased in approximately four fold steps, and final concentrations can be as high as 1 mM.

The preferred fermentation procedure is as fol¬ lows: the cotransformed host, preferably mammalian cells, more preferably Chinese hamster ovary (CHO) cells, is introduced into a culture medium containing nutrient materials that meet the growth requirements of the host cells. The host cells having the ampli¬ fied heterologous gene are grown under culturing con¬ ditions selected to achieve maximum growth rate. Tem¬ perature conditions will depend upon the host, with the typical optimum range about 35°C to about 39°C, with 37°C being the most preferred for transformed CHO cells. The copy number of the heterologous gene will typically be about 100 to about 3,000.

After the cells have reached an optimal density, the heat shock promoter is induced. During this step.

the temperature conditions are raised to about 40 C to about 45°C, with 43 C being the most preferred tem¬ perature condition. The temperature is kept at this level for transcription of the heterologous gene into messenger RNA (mRNA), typically from about 15 minutes to about 180 minutes.

After the heat shock, the cells and mRNA are al¬ lowed to recover from the heat at a lower temperature and for a time sufficient to produce or translate the heterologous polypeptide from the messenger RNA tem¬ plate. The preferred temperature is about 35 C to about 39°C more preferably about 37°C. Recovery and production time is typically from about 60 to about 600 minutes.

The produced heterologous polypeptide may be .re¬ covered according to means known in the art. Using the method of this invention, the level of polypeptide or protein produced is 20 to 100 fold higher than that produced by a constitutive promoter. The preferred embodiment of this invention is particularly useful when the heterologous polypeptide or protein impairs the growth of the transformed host cell. This method can accomplish induction of the promoter to expression of the heterologous gene within about 5 hours.

The following examples further describe the mater¬ ials and methods used in carrying out the invention. The examples are not intended to limit the invention in any manner.

Examples

In the following examples, these procedures were used:

Cells

Dihydrofolate-reductase deficient CHO cells (CHO-DUKX Bl) were obtained from L. Chasin, Columbia University, New York. Urlaub, G. et al., Proc. Natl. Acad. Sci. USA, 77:4216-4220 (1980). Prior to transfection, cells were grown in alpha-modified MEM with 10% dialized PCS to which adenosine, deoxya- denosine and thymidine were added to a final concen¬ tration of 10 ug/ml each. Cells containing DHFR- plasmids were maintained in alpha-modified MEM supplemented with 10% dialyzed FCS and containing the indicated amount of the drug methotrexate. DNA Transfection and Amplification

CHO-DUKX Bl cells were transfected by a modifi¬ cation of the calcium phosphate coprecipitation technique of Graham and Van der Eb, described in Graham, F.L. et al.. Virology, 52:456-467(1973) and Kingston, R.E. et al. , Mol. Cell. Biol., 4: 1970-1977 (1984). Clones were picked using cloning cylinders and six independent cell lines were established, from which four cell lines (4-HS-MYC, 5A-HS-MYC, 5B-HS-MYC, 6A-HS-MYC) were grown in stepwise 4-fold increasing concentrations of methotrexate, starting with a concentration of 0.005 uM. Cells were allowed to acclimate to each increased level of selection for two to four weeks before again increasing the concentra¬ tion of methotrexate. All cell lines were finally established in 320 uM methotrexate. Plasmids

The plasmid pCVSVEII has been described in Kingston, R.E. et al., Mol. Cell. Biol., 4: 1970-1977 (1984). The plasmid pHSmyc was constructed as fol-

lows: ρSV2myc (Land, H. et al.. Nature, 304:596-601 (1983)) was cut with Xba I, blunted with Klenow poly- merase, then cut with BamHI in order to isolate the c-myc genomic fragment. This fragment was cloned into Hindi and BamHI cut pSP6-HS-9 to obtain pHSmyc. pSP6-HS-9 was constructed by isolating the promoter containing Hindlll/PstI fragment from p232.3 (Holm¬ gren, ^' R. et al.. Cell, 18:1359-1370 (1979)), which contains a Drosophila heat shock protein 70 promoter, and then cloning this fragment into Pstl/Hindlll cleaved pSP65. Analysis of RNA and DNA

Isolation and analysis of cytoplasmic RNA was performed as described in Favaloro, J. et al. , Meth. Enzymology, 65:718-742 (1980) and Melton, D.A. et al. , Nucl. Acids Res. 12:7035-7056 (1984) using radiola- belled RNA probes prepared with SP6 polymerase. Analy¬ sis of genomic DNA from cell lines was performed ac¬ cording to Southern using minigels for separation of restricted DNA and radiolabelled RNA-probes synthe¬ sized by SP6 polymerase. Induction of Recombinant Cell Lines

Recombinant cells were split the day before induc¬ tion to have a density of 60 to 80% of confluence in 10 cm petri dishes. They were heat shocked by feeding with medium that had been prewarmed to 43 C, and kept at that temperature in an incubator for 1 to 4 hours, preferably 2 hours. The medium was changed again after that period in order to have the cells recover at 37°C for 1 to 9 hours, preferably for 2 to 4 hours. Analysis and Identification of c-myc Proteins

For lysis of cells 2 ml RIPA buffer (Klemens, R. , Embo J., 4:2053-2060 (1985)) was added to 50-60% confluent cells in 10 cm dishes. Cells were scraped

off immediately with the help of a rubber policeman and the highly viscous solution was sonicated 3 times 5 seconds each on ice. SDS-PAGE and Western blot analysis were performed using 12% gels (Hann, S.R., and Eisenman, R.N. (1984) Mol. Cell. Biol., 4_:2486- 2497 (1984)). For immunodetection of c-myc proteins polyclonal and monoclonal antibodies, raised against human c-myc protein, were used. These antibodies were a gift from R. Chizzonite, HofmannLaRoche, Nutley. To immunoprecipitate 32-phosphate labelled cellular proteins, 100 ul sonicated RIPA-buffer lysate was incubated with 25 ul protein A sepharose (Pharmacia) overnight at 4°C while rocking. The suspension was then centrifuged for 15 minutes at 13500 x g. One ul of monoclonal anti-c-myc antibody was added to the supernatant and the mixture was incubated at room temperature for 1.5 hour. Then 5 ul of rabbit anti-mouse IgG (affinity purified, 250 ug/ml, Cappel, Cooper Biomedical) together with 20 ul protein A sepharose was added. The suspension was incubated at 4°C for 2 hours on a rocking wheel and then centrifuged 10 minutes at 13500 x g. The sediment was washed 3 times with each 1 ml RIPA buffer contain¬ ing 0.5 m NaCl before resuspending in 50 ul 2x Laemmli sample buffer. The sample was heated for 3 minutes at 100°C and an aliquot of 15 ul used for loading on the SDS-polyacrylamide gel. Radiolabelled S35-methionine and acid free Phosphate were obtained from NEN. La¬ belling of cellular proteins was performed by deplet¬ ing the cells from the respective component during heatshock and adding the labelled component during the recovery time.

Example 1

Amplification of the c-ymc Gene in CHO Cells

An initial attempt was made to overexpress the c-myc protein by introducing the gene on a constitu¬ tive promoter (pSV2-cmyc) into the DHFR deficient CHO- DUKX Bl cell line using DHFR expression as a selec¬ tion. Colonies that formed after this transfection had an abnormal phenotype; very few of the selected colonies grew into stable lines, and only one of the three resultant stable lines expressed c-myc RNA (data not shown). The cells of this line looked extremely refractile and grew poorly, suggesting that constitut¬ ive overexpression of c-myc may be cytotoxic. There¬ fore, plasmid pHS-myc was constructed. (Figure la). This plasmid links a Drosophila hsp70 promoter region, which has an extremely low basal level of expression, - and the second.,and third exons of a mouse c-myc gene isolated from a plasmacytoma (Shen-Ong, G.l. et al. , Cell, 31:443-450 (1982)). In pHA-myc, the first AUG 3' of the hsp70 transcription initiation site is that of the myc protein.

Figure la shows the construction of the ex¬ pression vector pHS-myc. This plasmid contains a ge¬ nomic mouse c-myc fragment from a unique Xbal site 48 bp upstream of the translation start codon in exon 2 to the unique BamHI site about 2.5 kb downstream of exon 3. The filled boxes denote the myc coding re¬ gion, the hatched boxes denote the remainder of mouse c-myc genomic sequences. The open box denotes the drosophila hsp70 promoter region, and the arrow de¬ notes the start site of the transcription. The fusion

between the promoter region and the c-myc gene is at +88 of the 5* untranslated region of the hsp70 pro¬ moter.

Figure lb shows the DHFR selection vector pCVSVEII-DHFR. The DHFR coding region is denoted by the solid box; splice and polyadenylation signals are denoted by the hatched box; and the adenovirus EII promoter and SV40 enhancer region are contained in the area denoted by the open box. Details of this plasmid are found in Kingston, R.E. et al., Mol. Cell Biol., 4_:1970-1977 (1984).

Plasmids pHS-myc (5 ug) and pCVSVEII-DHFR (1 ug) were introduced into DHFR deficient CHO DUKX Bl cells. Ten days after placing the cells in selection, indivi¬ dual colonies were cloned and subsequently expanded into cell lines. Six of the cell lines were tested for the presence of pHS-myc, and all contained the plasmid as determined by RNA analysis (described in Example 2). Four of these lines were cultivated in selective media containing stepwise increasing concen¬ trations of the drug methotrexate, an antagonist of DHFR function. This selection pressure results in amplification of the transfected DHFR gene and asso¬ ciated DNA in order to allow cell viability (Alt, F.W. et al., J. Biol. Chem. ,253:1357-1370 (1978) and United States Patent No. 4,399,216). After establishing these lines in 320 uM methotrexate, the copy number of the introduced c-myc gene in each cell line was deter¬ mined and compared with the copy number of the intro¬ duced c-myc gene in a cell line growing at different levels of methotrexate.

Figure 2 shows the copy number of the c-myc constructs in recombinant CHO cell lines. Genomic DNA was cleaved with Hindlll and subjected to agarose gel

electrophoresis and Southern transfer to nitrocellu¬ lose Genescreen Plus membranes (NEN). The membranes were then hybridized to an RNA probe, SP6 polymerase in vitro synthesized 32P-RNA containing the sequences of the Pstl-Hindlll fragment of c-myc exon 2, intron 2 and exon 3. The last lane on the right contains radiolabelled lkb-ladder DNA (BRL). Lanes 6-9 show genomic DNA (2 ug) isolated from four different recom¬ binant cell lines growing at 320 uM methotrexate. Lanes 13-16 show genomic DNA (0.5 ug) isolated from the cell line 5A-HS-MYC growing at different levels of methotrexate. Lanes 1-4 and 10-12 show genomic DNA isolated from the plasmid pHS-myc.

In comparison to reconstructions made using the plasmid pHS-myc, the recombinant cell lines contained approximately 900 (cell line 4), 2700 (cell line 5A), 90 (cell line 5B) and 1500 (cell line 6A) copies of the introduced c-myc gene. One of the four cell lines (6A) contained additional rearranged c-myc genes as well, as evidenced by the extra bands in Figure 2, lane 9. These levels of DNA were the result of ampli¬ fication of copy number during selection, as demon¬ strated for cell line 5A in Figure 2, lane 13-16.

Example 2 Induction of c-myc mRNA in Recombinant Lines

To determine whether transcription of the ampli¬ fied c-myc genes in the recombinant cell lines could be induced, RNA was isolated from growing cell lines incubated for 2 hours at 37°C or 43°C. Figures 3, A and B, show cytoplasmic RNA from uninduced (-) and heat shock induced (+) (2 hours at 43°C) recombinant

cells isolated and hybridized to 32P labelled RNA probe made using SP6 RNA polymerase that contained sequences of the entire Drosophila hsp70 promoter. The hybrid molecules were treated with RNasel in order to cleave single stranded regions. The resulting mo¬ lecules were separated on 6% non-denaturing polyacry- lamide gels.

In Figure 3A, lanes 1-10 show the results of analysis of RNA samples (10 ug) from different recom¬ binant cell lines as originally isolated in 0 metho¬ trexate. The cell line used is indicated in the figure. Lanes 11-16 show the results of analysis of RNA samples (5ug) from the line 5A-HS-MYC growing at different levels of methotrexate. In both the origin¬ al isolates of the cell lines (lanes 1-10) and the amplified cell lines (lanes 11-16), the amount of ap¬ propriately initiated message from the hsp70-c-myc fusion gene after heat shock was substantially in¬ creased. The level of RNA after induction increased as DNA copy number increased (lanes 11 to 16). The recombinant genes remain highly inducible even in the amplified cell lines (compare lanes 5 and 6 with lanes 15 and 16). It is difficult to quantitate the precise amount of induction due to the difficulty of detecting the basal level of expression.

Figure 3B shows RNA samples (3ug) from cell lines 4-HS-MYC (lanes 1-4), 5A-HS-MYC (lanes 5-8) and CHO-DUKX (lanes 9 and 10), analyzed as in A. RNA was isolated from cells growing at 37°C (lanes 1, 5 and 9), or from cells that had been incubated at 43°C for 2 hours and allowed to recover at 37°C for 1 hour (lanes 2 and 6), 2 hours (lanes 3, 7 and 10) or 3 hours (lanes 4 and 8).

In order to determine the integrity of the mes¬ sage, an RNA probe covering the second and third exons of c-myc was used. This probe revealed the same pri¬ mary RNA structure in the recombinant lines as for the endogenous c-myc gene in Balb-c 3T3 cells. Induced RNA levels in the recombinant lanes were at least 100 fold higher than observed for the endogenous gene of the Balb/c 3T3 cells. Figure 3C shows the comparison of c-myc mRNA sequences in Balb c/3T3, CHO-DUKX Bl cells and cells from recombinant CHO cell lines. Cy¬ toplasmic RNA (5ug) from cells kept at 37 C (-) and from cells induced for 2 hours at 43 C (+) was iso¬ lated, hybridized to a radiolabelled SP6 polymerase created RNA containing sequences of the Pstl-Hindlll fragment of the mouse c-myc gene (exon 2, intron 2 and exon 3), and digested with RNasel. The resulting molecules were analyzed on a 6% non-denaturing polyacryla ide gel. Lanes 1 and 2 (RNA from Balb/c 3T3 cells) and 3 and 4 (CHO DUKX cells) are shown as a 72 hour exposure, while lanes 5 to 12 (RNA from the indicated HS-MYC line) are an 8 hour exposure of the same gel.

A time ςourse demonstrated that c-myc RNA levels continued to increase with increasing time of heat shock through 3 hours (data not shown). As c-myc pro¬ tein synthesis does not occur in these lines at 43 C (described in Example 3), it was of interest to deter¬ mine if high RNA levels persisted when the heat in¬ duced cell lines were returned to 37°C. RNA levels remained relatively constant for three hours following the temperature shift (Figure 3B) .

Example 3 c-myc Protein Synthesis in Recombinant Lines

Initial attempts were made to detect the c-myc protein in recombinant cell lines immediately after a 2 hour heat shock at 43°C. There was no detectable c-myc protei-n made at that point as judged by pulse labelling with S-methionine or by immunoblotting. In contrast, however, when cells were allowed to recover at 37°C after the 2 hour heat shock, c-myc protein was detectable by immunoblotting and the level of protein increased with increasing time of recovery.

Figures 4, A and B, show the time course of induction of c-myc protein and analyses of protein levels in induced cells. RIPA-buffer lysates (2ml) were prepared from 70-80% confluent cells in 10 cm dishes after growing them at 37 C (Figure 4A: lanes 1,

5, 9, 11; Figure 4B: lanes 1, 3, 7) and after heat shock induction for 2 hours at 43°C and varying time period of recovery at 37°C (Figure 4A: lanes 2 and 6, 1 hour recovery; lanes 3, 7 and 10, 2 hours recovery; lanes 4 and 8, 3 hours recovery; Figure 4B: lane 4, 1 hour recovery; lanes 2 and 5, 2 hours recovery; lane

6, 3 hours recovery). Lysates were applied to 12% SDS-PAGE (20 ul per sample) and proteins transferred electrophoretically onto nitrocellulose filter paper IS+S, BA 85). c-myc proteins were detected by incubation with anti c-myc monoclonal antibodies (R. Chizzonite, Hoffmann-LaRoche; 1:2000 diluted) and ¹²⁵ Iodine labelled Protein A (NEN). In Figure 4B, lanes 8 and 9 contain purified c-myc (lane 8; 10 ug, lane 9; 50 ug) derived from recombinant insect cells (G. Ju, Hoffmann-LaRoche).

Three bands were observed with relative mobilities of 64,000, 66,000 and 75,000 that were recognized by either monoclonal or polyclonal antibodies raised

against a portion of the human c-myc protein that is conserved in mouse c-myc (Miyamoto, C. et al. , Mol.

Cell. Biol., 5:2860-2865 (1985)). The smaller two of these have been seen in previous studies (Schwab, M. et al.. Nature, 315:345-347 (1985); Hann, S.R. et al.,

Cell, 34:789-798 (1983); Ramsay, G. , Proc. Nat'l.

Acad. Sci. USA, 81:7742-7746 (1984); and Hann, S.R., and Eisenman, R.N. Mol. Cell. Biol., 4_:2486-2497

(1984)).

The amount of c-myc protein produced by the 5A-HS-

MYC line is at least twofold higher than the amount obtained from the 4-HS-MYC line, which has a lower copynumber of the c-myc construct. By comparing levels of protein with a purified protein produced in an insect expression vector (Miyamoto, C. et al. , Mol.

Cell. Biol., 5:2860-2865 (1985)), it was estimated

9 that 10 CHO cells produce approximately 1 mg of c-myc protein (Figure 4B, compare lanes 6 and 9). These lines produce substantially more c-myc protein than the human tumor line COLO 320 HSR (Schwabb, M. et al. , Nature, 315:345-347 (1985)), which contains approxi¬ mately 20 copies of an endogenous c-myc gene (compare lanes 8 and 11 in Figure 4A and lanes 6 and 7 in Fig¬ ure 4B) .

The presence of high levels of c-myc protein during the recovery period implies that c-myc is one of the more abundant proteins made in the recombinant lines during this time. This was verified as shown in Figure 4C. Figure 4C shows that the c-myc protein is one of the major proteins synthesized in the recom¬ binant lines during recovery and it made as a phospho- protein. RIPA buffer lysates of 35S methionine (lanes 1-14) and 35phosphate labelled proteins (lanes 5-10,

immunoprecipitation: lanes 11-17), separated on 12% SDS-PAGE. Immunoprecipitation was performed as described above. Protein isolates were from the indicated cell line either growing at 37°C (-) or induced for 2 hours at 43°C (+) and allowed to recover at 37°C for either 2 hours (lanes 2, 4, 6, 9, 12 and 15) or 4 hours (lanes 7, 10, 13, 16 and 17). Lane 17 is a light exposure of lane 16. Analysis of the resultant cell lysates reveals that c-myc is one of the most actively synthesized proteins in cell line 5A during this period between 1 and 3 hours after heat shock (Figure 4C, lane 4).

The mammalian c-myc protein has been shown to be phosphorylated (Hann, S.R. et al. _f Cell, 34:789-798 (1983), Ramsay, G. , Proc. Nat'l Acad. Sci USA, 81: 7742-7746 (1984), and Hann, S.R. , and Eisenman, RN. , Mol. Cell. Biol., 4:2486-2497 (1984)). The c-myc pro¬ tein produced in recombinant cell lines 4 and 5A is also phosphorylated, and is the major phosphoprotein labelled during the recovery priod (Figure 4C, lanes 6, 7 and 9, 10). Immunoprecipitation reveals that all three species of the c-myc protein appear to be phosphorylated. (Figure 4C, lanes 12, 13, and 15-17). A culture of the 5A-HS-MYC cell line was deposited with no restriction at the American Type Culture Collection, 12301 Parklawn Dr., Rockville, Maryland 20852, under ATCC No. CRL 9010 on February 4, 1986. This depository assures permanence of the deposit and ready accessibility thereto by the public.

Example 4 Viability of Cell Lines After Induction of c-myc

Initial experiments had raised the possibility that overproduction of c-myc is cytotoxic. To test this hypothesis, the viability of the recombinant lines after induction of c-myc was investigated. Re¬ combinant lines were plated at a density of approxi¬ mately 10 /10cm dish, left at 37°C for 5 hours, and then either heat shocked for 2 hours at 43°C and then returned to 37°c, or left at 37°C. After 2 days at 37°C, no living cells were left on the dish of recom¬ binant cells that had been heat shocked, while the control dish of the recombinant line as well as both the heat shock and control dishes of the parallel line were confluent. Similar results were obtained with the other three recombinant lines. Microscopic exami¬ nations of. the cells during this recovery period re¬ vealed that they slowly died without further cell di¬ vision after induction of c-myc.

The foregoing invention has been described in some detail by illustration and example for purposes of clarity and understanding. It would be obvious that certain changes and modifications may be practiced within the scope of the invention, as limited only by the scope of the appended claims.

PCT Appl icant' s Guide - Volume I - Annex M3

ANNEX H3

International Application No: PCT/

MICROORGANISMS

Optional S aat In connection wtth the microorganfam lotoriod to on page. 26 24 . of the deeerlptton t

. IDENTIFICATION OP DEPOSIT <

Further deooeite are Identified on an additional eheet Q«

Name e< depoettary Inatttutlon «

AMERICAN TYPE CULTURE COLLECTION

Addreaa of dβpotttary Inat utiβn (Including poetal code end country) *

12301 Parklawn Drive Rockville, Maryland 20852 United Stαtoo of ΛmoB ca

Oato of dapoait * Acceaefon Number •

04 February 1986 CRL 9010

B. AOOITIONAL INOICATIONS ' (leave blank If not applicable). Thia information la continued on a aeperate attached aheet Q

Chinese Hamster Ovary Cells DUK Bl

C OCSI6NATCO STATES FOR WHICH INOICATIONS ARC NAOE > (if tha indleaUona are not for all daelβnated Statea)

O. SEPARATE FHRNISHIN6 OF INOICATIONS • (leave Wank if not applicable)

The indicaliona liatad below will be aubmitted to the International Bureau later • (Specify the general nature of the Indleationt e.g.. " Acceaalon Number ot Oepout ")

E. _~\ Thia aheet waa received with tne international application wnan riled (to be checkad by tha receiving Office)

(Authorized Officer) [~1 The data of receipt (from tha applicant) by the International Bureau >'

waa =

(Authorized Officer) r -=3 β_